These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21490076)

  • 1. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program.
    Child CJ; Zimmermann AG; Scott RS; Cutler GB; Battelino T; Blum WF;
    J Clin Endocrinol Metab; 2011 Jun; 96(6):E1025-34. PubMed ID: 21490076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.
    Cutfield WS; Wilton P; Bennmarker H; Albertsson-Wikland K; Chatelain P; Ranke MB; Price DA
    Lancet; 2000 Feb; 355(9204):610-3. PubMed ID: 10696981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program.
    Child CJ; Zimmermann AG; Chrousos GP; Cummings E; Deal CL; Hasegawa T; Jia N; Lawrence S; Linglart A; Loche S; Maghnie M; Pérez Sánchez J; Polak M; Predieri B; Richter-Unruh A; Rosenfeld RG; Yeste D; Yorifuji T; Blum WF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):379-389. PubMed ID: 30219920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Primary Cancer Incidence in Growth Hormone-Treated Children: Comparison of a Multinational Prospective Observational Study with Population Databases.
    Child CJ; Zimmermann AG; Jia N; Robison LL; Brämswig JH; Blum WF
    Horm Res Paediatr; 2016; 85(3):198-206. PubMed ID: 26913923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis.
    Attanasio AF; Jung H; Mo D; Chanson P; Bouillon R; Ho KK; Lamberts SW; Clemmons DR;
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2255-61. PubMed ID: 21543424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls.
    van Dijk M; Bannink EM; van Pareren YK; Mulder PG; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2007 Jan; 92(1):160-5. PubMed ID: 17062774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement.
    Attanasio AF; Mo D; Erfurth EM; Tan M; Ho KY; Kleinberg D; Zimmermann AG; Chanson P;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):74-81. PubMed ID: 19897679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group.
    Rappaport R; Mugnier E; Limoni C; Crosnier H; Czernichow P; Leger J; Limal JM; Rochiccioli P; Soskin S
    J Clin Endocrinol Metab; 1997 Feb; 82(2):452-6. PubMed ID: 9024235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
    Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children.
    Johannsson G; Albertsson-Wikland K; Bengtsson BA
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4516-24. PubMed ID: 10599711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth and management of short stature in thalassaemia major.
    Theodoridis C; Ladis V; Papatheodorou A; Berdousi H; Palamidou F; Evagelopoulou C; Athanassaki K; Konstantoura O; Kattamis C
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():835-44. PubMed ID: 10091154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
    Audí L; Carrascosa A; Esteban C; Fernández-Cancio M; Andaluz P; Yeste D; Espadero R; Granada ML; Wollmann H; Fryklund L;
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
    de Zegher F; Du Caju MV; Heinrichs C; Maes M; De Schepper J; Craen M; Vanweser K; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency.
    Sas T; Mulder P; Hokken-Koelega A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3786-92. PubMed ID: 11061539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA; Mul D; Waelkens JJ; Jansen M; Delemarre-van de Waal HA; Verhoeven-Wind L; Frölich M; Oostdijk W; Wit JM
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prevalence of type 1 diabetes in children aged <15 yr in Castilla-Leon (Spain).
    Bahíllo MP; Hermoso F; Ochoa C; García-Fernández JA; Rodrigo J; Marugán JM; de la Torre S; Manzano F; Lema T; García-Velázquez J;
    Pediatr Diabetes; 2007 Dec; 8(6):369-73. PubMed ID: 18036062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone.
    Holmer H; Svensson J; Rylander L; Johannsson G; Rosén T; Bengtsson BA; Thorén M; Höybye C; Degerblad M; Bramnert M; Hägg E; Edén Engström B; Ekman B; Norrving B; Hagmar L; Erfurth EM
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3560-7. PubMed ID: 17623762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
    Fjellestad-Paulsen A; Simon D; Czernichow P
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1234-9. PubMed ID: 15001616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables.
    Ranke MB; Lindberg A;
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1229-37. PubMed ID: 20097713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.